ID

33252

Description

Study ID: 107434 Clinical Study ID: NAP107434 Study Title: A randomised, double-blind, double-dummy, placebo controlled, three-way cross-over study to investigate the effect of single oral doses of 100 mg GW273225 (4030W92) and 325 mg LAMICTAL on resting motor threshold in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Study Link: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GW273225 Trade Name: lamictal Study Indication: Bipolar Disorder This form records updates in the medical history of the subject. It should be checked at each visit after the screening. Screening Visit: 28 days prior to first dosing. Treatment Period: The day before dosing, until 48h after dosing. Follow-Up: 14-21 days after last dose

Mots-clés

Versions (4)

1. 03/12/2018 03/12/2018 -
2. 16/12/2018 16/12/2018 -
3. 09/01/2019 09/01/2019 -
4. 11/01/2019 11/01/2019 - Sarah Riepenhausen

Détendeur de droits

GlaxoSmithKline

Téléchargé le

3 décembre 2018

DOI

Pour une demande vous connecter.

Licence